Pharma IQ spoke to Jeremy Schafer and Scott Marshall to find out their predictions.
The manufacturing and clinical landscapes are set to see further change over the coming years. Pharma IQ spoke to Jeremy Schafer and Scott Marshall to find out their predictions.
Jeremy Schafer, PharmD, MBA, SVP, Access Experience Team, Precision for Value
Gene therapies and potential cures
Diseases that have been managed for decades through chronic drugs may see dramatic paradigm shifts in care through the development of gene therapies.
2019 could see a monumental change in how diseases like hemophilia, immunodeficiency, and cancer are treated.
We will also begin to gather more data on the durability of gene and CAR-T therapies already on the market, which will help us understand whether these therapies are worthwhile investments and how manufacturers will continue to evolve the science.
Federal and State pressure on prices
Democrats, who will assume control of the House in 2019, found a winning message on healthcare during the midterms. Thy will likely keep up the pressure with a focus on drug prices, an issue where the electorate places a high priority.
Combined with a President who has shown a willingness to be aggressive and inventive in implementing ways to reduce costs, manufacturers will be more pressured on price than ever before. Read more here.
